Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747575 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT03747575 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 65 participants.
The verdict
NCT03747575, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
Interventions
- DRUG Placebo
- DRUG MSTT1041A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2020-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03747575
The ClinicalTrials.gov registry entry for NCT03747575 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03747575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03747575 about?
NCT03747575 is a clinical study titled "A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis". This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
What is the current status of trial NCT03747575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2019-02-06. Estimated completion is 2020-05-05.
What interventions are being tested in trial NCT03747575?
The interventions under investigation include: Placebo (DRUG), MSTT1041A (DRUG).
Who is sponsoring clinical trial NCT03747575?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.